Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this live activity for a maximum of 7.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTINUING EDUCATION CREDIT (Pharmacists, Nurses, Nurse Practitioners, and Physician Assistants):
You will receive a certificate of attendance for the CME-certified sessions (those designated for AMA/PRA Category 1 Credits™) which may be submitted to state licensing boards for determination of credit reciprocity (conversion to CEUs).

Acknowledgment of Commercial Support

This activity is supported by educational grants from Astellas, AstraZeneca, Bristol-Myers Squibb, Celgene Corporation, Clovis Oncology, Foundation Medicine, Inc., Genentech, Lilly, Merck & Co., Inc., and Novartis Pharmaceuticals Corporation.

For further information concerning Lilly grant funding visit www.lillygrantoffice.com.

10th Annual New York Lung Cancer Symposium®

10th Annual New York Lung Cancer Symposium®

November 7, 2015
Crowne Plaza® Times Square Manhattan
New York, NY


This annual meeting will provide an update on advances in the current management of lung cancer, as well as a focus on the future.
Participants will have an opportunity to learn from engaging presentations delivered by leading experts. Sessions will include emerging data, discussions on evolving standards of care, tumor board style case reviews and information that has the potential to impact their practice in the short term. 

Target Audience

This educational activity is directed toward medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists involved in the treatment and management of patients with lung cancer.  Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of lung cancer may also participate.

Educational Objectives

At the conclusion of this activity, participants should be better prepared to:
  • Explain how to personalize treatment strategies for patients with advanced forms of lung cancer based on individual tumor characteristics
  • Discuss current and emerging immunooncology strategies in the context of clinical trial findings and patient selection in advanced forms of lung cancer
  • Describe current and emerging roles for agents that target the VEGF axis in advanced NSCLC
  • Delineate best practices concerning the application of targeted therapies in frontline- and subsequent settings of advanced lung cancer
  • Discuss evolving strategies to manage patients with acquired EGFR-TKI resistance in advanced NSCLC
  • Detail current and emerging clinical roles for ALK inhibition in the management of advanced NSCLC
  • Explain the current role of chemotherapeutic strategies as a method to personalize care in patients with lung cancer
  • Integrate personalized approaches to manage challenging cases in advanced lung cancer settings

Agenda Highlights

Workshop on Lung Cancer Immunotherapy in 2015
Key Data With Nivolumab (Anti PD-1) and Ipilimumab (Anti CTLA-4)
Current Status of Pembrolizumab (Anti PD-1) in Patients With Lung Cancer
Update on Clinical Trials of Atezolizumab (anti PD-L1) in Patients With Lung Cancer
Current Data and Ongoing Studies With Durvalumab (anti PD-L1) in Stage I-IV
How to Match the Right Agent to the Right Patient
How Might Immunotherapy Help Us Beat SCLC and Mesothelioma?
Targeting the VEGF Axis: Ligand and Receptor
New Applications for VEGF Antibodies
VEGF-Receptor Antibodies: The New Kid on the Block
Putting the Data into Practice: Challenging Cases in Lung Cancer
Challenging Cases
EGFR and ALK Inhibitors: Best Practices in 2015
Which EGFR TKI Do I Turn to First?
When Should I Change EGFR TKIs?
Third-Generation EGFR TKIs: How Have the Data Matured?
Applications of EGFR Antibodies in Frontline and TKI-Resistant Settings
An Update in the Landscape of ALK Inhibition
Putting the Data into Practice: Challenging Cases in Lung Cancer
More Challenging Cases
The Role of Chemotherapy in 2015
Cytotoxic Agents: When, and for How Long?

Click here to see the full agenda

Program Chairs

Mark G. Kris, MD
Attending, Thoracic Oncology Service
William and Joy Ruane Chair in Thoracic Oncology
Memorial Sloan Kettering Cancer Center
New York, NY

Roman Perez-Soler, MD
Chairman, Department of Oncology
Montefiore Medical Center
Professor of Medicine and Molecular Pharmacology
Deputy Cancer Center Director
Albert Einstein College of Medicine
Bronx, NY


You must be logged in to PER to register for this meeting

Or Register for PER now

*Required Fields

Login Information

Registration Information

In case of onsite emergency:

Professional Information


Calendar of Events
Filter By